Related Experiment Videos
Update on carcinoid syndrome
1Anesthesia Section, University of Minnesota, Minneapolis, USA.
AANA Journal
|June 1, 1997
Summary
Carcinoid syndrome, caused by tumor factors like serotonin, leads to flushing and heart issues. Preoperative assessment and octreotide are key for managing this condition.
Area of Science:
- Oncology
- Endocrinology
- Cardiology
Background:
- Carcinoid syndrome results from carcinoid tumor secretion of vasoactive substances.
- Key mediators include serotonin, kinins, and histamine.
- Manifestations involve flushing, hemodynamic instability, right-sided heart disease, bronchospasm, and GI symptoms.
Purpose of the Study:
- To outline essential preoperative assessments for carcinoid syndrome.
- To discuss perioperative management strategies.
- To highlight optimal medical therapy for carcinoid syndrome.
Main Methods:
- Comprehensive preoperative evaluation focusing on potential complications.
- Utilization of invasive monitoring during the perioperative period.
- Careful avoidance of drugs and techniques that may worsen the syndrome.
Main Results:
- Thorough assessment identifies high-risk patients.
- Perioperative monitoring and drug avoidance mitigate risks.
- Octreotide demonstrates efficacy in both prophylaxis and acute management.
Conclusions:
- Meticulous preoperative assessment is crucial for managing carcinoid syndrome.
- Perioperative care should involve invasive monitoring and avoidance of exacerbating agents.
- Octreotide is the leading medical treatment for carcinoid syndrome, used both preventatively and acutely.